| Howard Hutchinson, MD, Chief Medical Officer, AstraZeneca - Video CRESTOR™ GAINS NEW EU INDICATION TO PREVENT MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK PATIENTS feedproxy.google.com |
J&J Wins Drug Ruling A state judge handed a victory to J&J, dismissing a Pennsylvania government lawsuit over its marketing of an antipsychotic drug. online.wsj.com |
Vivus's Implied Volatility Gets Extreme Bill Luby submits: From time to time I have highlighted extremely high implied volatility in individual securities such as FAS, Interoil (IOC), EWZ and the banks that were subject to the stress tests. With the recent action in Vivus (VVUS), however, it may be time to reconsider just how extreme implied volatility can get. Vivus has a new weight-loss pill, Qnexa, that is under review by the FDA, with a decision expected Thursday. For those who are interested in the details, Business Week provides a handy summary of the situation in Vivus’s Diet Pill Qnexa Faces FDA Scrutiny on Safety.Complete Story » seekingalpha.com |
Malaria Drug Candidate Holds Promise An international team of scientists has identified a promising drug candidate that represents an entirely new class of medicines to treat malaria, one of the biggest killers in the developing world. online.wsj.com |
InSight Imaging Reports Results for the Fourth Quarter and Fiscal Year Ended June 30, 2010 [Business Wire] - LAKE FOREST, Calif.----InSight Health Services Holdings Corp. today announced its financial results for the fourth quarter and fiscal year ended June 30, 2010. us.rd.yahoo.com |